Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Unilateral HER2 Positive Breast Cancer × Afatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 45 Neoplasms 18 Breast Neoplasms 9 Head and Neck Neoplasms 8 Squamous Cell Carcinoma of Head and Neck 6 Lung Neoplasms 6 Stomach Neoplasms 3 Neoplasm Metastasis 3 Colorectal Neoplasms 3 Glioblastoma 2 Carcinoma, Squamous Cell 2 Adenocarcinoma 2 Urologic Neoplasms 1 Unilateral HER2 Positive Breast Cancer 1 Thoracic Neoplasms 1 Squamous Non-small Cell Lung Cancer 1 Squamous Cell Cancers of the Head and Neck 1 Solid Tumors 1 Rhabdomyosarcoma 1 Respiratory Tract Neoplasms 1 Respiratory Tract Diseases 1 Prostatic Neoplasms 1 Pleural Neoplasms 1 Pleural Effusion, Malignant 1 Pleural Effusion 1 Pleural Diseases 1 Pancreatic Neoplasms 1 Oligodendroglioma 1 Neuroectodermal Tumors 1 Neoplasms, Squamous Cell 1

Interventions

Trastuzumab 1 Paclitaxel 1 Epirubicin 1 Cyclophosphamide 1 Afatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01594177 2014-03-13

DAFNE

GBG Forschungs GmbH

Phase 2 Completed

Unilateral HER2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡